drugset

drugset / Trial / NCT05084027

Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT

NCT05084027 ↗

Phase 2 Unknown 50 enrolled First Affiliated Hospital of Zhejiang University First Affiliated Hospital of Wenzhou Medical University · collab Ningbo Hospital of Zhejiang University · collab Second Affiliated Hospital, School of Medicine, Zhejiang University · collab Sir Run Run Shaw Hospital · collab The Affiliated People's Hospital of Ningbo University · collab The First Affiliated Hospital of Zhejiang Chinese Medical University · collab Zhejiang Provincial People's Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for older patients with hematologic malignancies

Timeline

Start: 2021-10-07
Primary completion: 2022-09-30
Completion: 2024-09-30

Publications

Lai X, Zhu P, Yang L, Liu L, Wu Y, Shi J, Yu J, Zhao Y, Ouyang G, Chen Y, Ye Y, Zhang P, Sun L, Zheng W, Sun J, Huang H, Luo Y. Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial. Cancer. 2026 Jun 1;132(11):e70467. doi: 10.1002/cncr.70467.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fludarabine	Small molecule	30 mg/m2	Intravenous
Subject	Melphalan	Small molecule	140 mg/m2	Intravenous
Subject	Venetoclax	Small molecule	400 mg	Oral

Indications